Current status and challenges of antiretroviral research and therapy

被引:208
作者
Este, Jose A. [1 ]
Cihlar, Tomas [2 ]
机构
[1] Univ Autonoma Barcelona, Retrovirol Lab IrsiCaixa, Hosp Germans Trias & Pujol, Badalona, Spain
[2] Gilead Sci Inc, Foster City, CA 94404 USA
关键词
HIV; Antiretrovirals; Special issue; REVERSE-TRANSCRIPTASE INHIBITORS; TREATMENT-NAIVE PATIENTS; HIV-1; INFECTION; SEXUAL TRANSMISSION; CLINICAL-OUTCOMES; SPARING REGIMENS; TENOFOVIR DF; DOUBLE-BLIND; VIRUS; AIDS;
D O I
10.1016/j.antiviral.2009.10.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Twenty-five years after the discovery of the therapeutic activity of azidothymidine (AZT), the first antiretroviral drug used in the clinic, infection with the human immunodeficiency virus (HIV) has become, at least in the industrialized world, a manageable chronic disease with a significant improvement in life expectancy and quality. Nevertheless, the number of new infections worldwide continues to rise, particularly in women, and effective drug treatments have not yet reached the vast majority of infected individuals in resource-limited countries. The current status of antiretroviral therapy is therefore encouraging, but significant challenges remain. Although highly active antiretroviral therapy (HAART) provides durable control of virus replication in many patients, it is not devoid Of unwanted secondary effects, some of which are now surfacing in aging populations under long-term treatment. The emergence of multidrug resistance and transmission of drug-resistant HIV strains lit-nit the clinical efficacy of current therapy. Further simplification of treatment and identification of more effective drug combinations are needed to improve patient adherence, the most significant cause of treatment failure. Finding new drugs and novel drug targets may lead to redefining the goals of antiretroviral therapy, with an attempt to achieve the ultimate objective: the eradication of infection. Preclinical and clinical biomedical research, rational drug design and a close collaboration with regulatory agencies to set standards for the transition of new treatment concepts into the clinic will be the cornerstones of future progress. This special issue of Antiviral Research [85(1), 2010] highlights the principal milestones of antiretroviral research over 25 years of drug discovery and development and offers a comprehensive analysis by leading experts of the efforts being made to meet the challenges of effective control of HIV infection. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, vol. 85. issue 1, 2010. (C) 2009 Elsevier B.V. All rights reserved
引用
收藏
页码:25 / 33
页数:9
相关论文
共 101 条
[21]   Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009) [J].
de Bethune, Marie-Pierre .
ANTIVIRAL RESEARCH, 2010, 85 (01) :75-90
[22]   In search of a selective therapy of viral infections [J].
De Clercq, Erik .
ANTIVIRAL RESEARCH, 2010, 85 (01) :19-24
[23]   Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration [J].
Detels, R ;
Muñoz, A ;
McFarlane, G ;
Kingsley, LA ;
Margolick, JB ;
Giorgi, J ;
Scharager, LD ;
Phair, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (17) :1497-1503
[24]   Pharmacokinetics and drug-drug interactions of antiretrovirals: An update [J].
Dickinson, Laura ;
Khoo, Saye ;
Back, David .
ANTIVIRAL RESEARCH, 2010, 85 (01) :176-189
[25]   Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women [J].
Dumond, Julie B. ;
Patterson, Kristine B. ;
Pecha, Allison L. ;
Werner, Rebecca E. ;
Andrews, Emma ;
Damle, Bharat ;
Tressler, Randall ;
Worsley, Jochen ;
Kashuba, Angela D. M. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 (05) :546-553
[26]   CHALLENGES FOR THE DEVELOPMENT OF FEMALE-CONTROLLED VAGINAL MICROBICIDES [J].
ELIAS, CJ ;
HEISE, LL .
AIDS, 1994, 8 (01) :1-9
[27]   Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study [J].
Emery, Sean ;
Neuhaus, Jacqueline A. ;
Phillips, Andrew N. ;
Babiker, Abdel ;
Cohen, Calvin J. ;
Gatell, Jose M. ;
Girard, Pierre-Marie ;
Grund, Birgit ;
Law, Matthew ;
Losso, Marcelo H. ;
Palfreeman, Adrian ;
Wood, Robin .
JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (08) :1133-1144
[28]  
ESTE JA, 2010, ANTIVIRAL RES, V85
[29]   HIV entry inhibitors [J].
Este, Jose A. ;
Telenti, Amalio .
LANCET, 2007, 370 (9581) :81-88
[30]   Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection [J].
Faetkenheuer, Gerd ;
Nelson, Mark ;
Lazzarin, Adriano ;
Konourina, Irina ;
Hoepelman, Andy I. M. ;
Lampiris, Harry ;
Hirschel, Bernard ;
Tebas, Pablo ;
Raffi, Francois ;
Trottier, Benoit ;
Bellos, Nicholaos ;
Saag, Michael ;
Cooper, David A. ;
Westby, Mike ;
Tawadrous, Margaret ;
Sullivan, John F. ;
Ridgway, Caroline ;
Dunne, Michael W. ;
Felstead, Steve ;
Mayer, Howard ;
van der Ryst, Elna .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (14) :1442-U46